跳至主要内容
临床试验/NCT05225935
NCT05225935已完成不适用

Computed Tomography-Guided Catheter Ablation for Ventricular Tachycardia (InEurHeart Study)

University Hospital, Bordeaux16 个研究点 分布在 4 个国家目标入组 119 人开始时间: 2022年6月29日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
119
试验地点
16
主要终点
Procedure duration

研究概览

简要总结

This double arm randomized study will compare 2 ventricular tachycardia ablation strategies: the standard strategy based on invasive substrate and VT mapping with 3D electro-anatomical system vs a tailored strategy which identifies targets based on pre-procedural CT-scan imaging. The primary endpoint will be procedure duration and secondary endpoints will include safety and efficacy criteria as well as medico-economic evaluation.

详细描述

Ventricular tachycardia ablation is a non-drug alternative for patients with recurrent VT and ischemic cardiomyopathy with a class 1 indication in the latest guidelines. However, it is poorly standardised and reserved to expert centres. Proof of concept studies have demonstrated that image-guided VT ablation is feasible, and that it may improve the efficiency of VT ablation.

Ablation strategy no longer relying on intracardiac 2-dimensional surface catheter measurements for target identification, but on 3- dimensional pre-operative images of the myocardium acquired by computed tomography (CT) would shorten the procedure, make it more reproducible and less dependent of the operator's experience without altering efficacy.

This randomized study will compare VT ablation based on substrate/VT isthmus identification via intracardiac catheter vs identification via pre-procedural CT-scan. Ablation will be performed with the same material.

Primary endpoint will be procedure duration. Secondary endpoints will compare efficacy and safety of both strategies as well as cost-effectiveness.

Expected results are a reduction procedure duration, without alteration of the efficacy for the CT-guided procedure with an improved medico-economic evaluation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years,
  • Indication for catheter ablation intervention with planned preoperative cardiac CT scan
  • Prior myocardial infarction (using the international definition of MI: Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non- ischemic cause with documentation of prior ischemic injury),
  • Presence of an implantable cardioverter defibrillator, or planned ID implantation before discharge, and
  • One of the following monomorphic VT events within last 6 months:
  • A: ≥3 episodes of VT treated with antitachycardia pacing (ATP),
  • B: ≥1 appropriate ICD shocks,
  • C: sustained VT below detection rate of the ICD documented by ECG or any cardiac monitor
  • D: Sustained VT recorded on 12 leads ECG in the absence of ICD
  • Highly effective contraception for women of childbearing potential, maintained during research procedures
  • Signed informed consent ,
  • Affiliated to or beneficiary of a health insurance

排除标准

  • Unable to understand the nature, risks, significance and implications of the clinical investigation or unwilling to provide written informed consent,
  • Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days thought to be due to acute coronary arterial thrombosis, or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia,
  • Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves,
  • Have had a prior catheter ablation procedure for VT,
  • Presenting arrhythmia: polymorphic VT or ventricular fibrillation (VF),
  • Renal failure (Creatinine clearance <30 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year,
  • Women who are pregnant, lactating, or who are planning to become pregnant during the anticipated study period,
  • Patient under legal protection

研究组 & 干预措施

image-guided VT ablation strategy

Experimental

Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets

干预措施: image-guided VT ablation strategy (Device)

conventional VT ablation strategy

Active Comparator

Catheter ablation performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.

干预措施: conventional VT ablation strategy (Device)

结局指标

主要结局

Procedure duration

时间窗: Day 1

Procedure duration measured from the first introduction of a catheter in the cardiac chamber of interest (mainly left ventricle or epicardial space) to the end of the last radiofrequency application

次要结局

  • Sustained VT not treated by ICD >14 days after procedure(Month 1, Month 6, Month 12)
  • anti-arrhythmic drugs(Month 1, Month 6, Month 12)
  • Inappropriate ICD shock >14 days after procedure(Month 1, Month 6, Month 12)
  • Electrical storm >14 days after procedure(Month 1, Month 6, Month 12)
  • Number of VT(Baseline, Month 6, , Month 12)
  • Appropriate ICD shock >14 days after procedure(Month 1, Month 6, Month 12)
  • Appropriate antitachycardia pacing from ICD >14 days after procedure(Month 1, Month 6, Month 12)
  • Death(Month 12)
  • Payer healthcare costs(Month 1, Month 3, Month 6, Month 9, Month 12)
  • Incremental cost per QALY gained(Month 1, Month 3, Month 6, Month 9, Month 12)
  • General health-related quality of life(Baseline, Month 1, Month 6, Month 12)
  • Quality-adjusted life(Month 1, Month 3, Month 6, Month 9, Month 12)
  • Incremental cost per VT episode avoided(Month 1, Month 3, Month 6, Month 9, Month 12)
  • Radiofrequency (RF) applications(Day 1)
  • Societal healthcare costs(Month 1, Month 3, Month 6, Month 9, Month 12)
  • Incremental cost per additional day without a VT episode(Month 1, Month 3, Month 6, Month 9, Month 12)

研究者

发起方
University Hospital, Bordeaux
申办方类型
Other
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验